2019
DOI: 10.23937/2377-4630/1410086
|View full text |Cite
|
Sign up to set email alerts
|

Perioperative Management in Patients with Factor XI Deficiency

Abstract: hemoglobin count 10.6 g/dl. Prothrombin time (PT) was 100% (normal range: 70%-100%), activated partial thromboplastin time (APTT) with normal plasma [ratio 1:1] was 1.24 (Normal range: 0.80-1.20). Her laboratory evaluation revealed an FXI level quantitated at 41%.A routine hematology consultation was obtained and a bleeding management strategy was established that was performing the surgical procedure with antifibrinolytic therapy with tranexamic acid (1 g twice a day, for 10 days), avoid nonsteroidal antiinfl… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 6 publications
0
1
0
Order By: Relevance
“…Severe FXI deficiency is defined as activity level <20%, and partial or mild FXI deficiency is defined as levels between 20% and 60% 8 . However, the bleeding risk does not correlate well with FXI activity level, and the unpredictability of bleeding risk intraoperatively and postoperatively make the perioperative management of these patients particularly challenging 8,9 . Therapeutic agents available for management of FXI deficiency include FFP, FXI concentrate, antifibrinolytic agents such as ε‐aminocaproic acid or tranexamic acid, desmopressin, and low‐dose activated recombinant factor VII before surgery have been used to prevent bleeding complications 1 .…”
Section: Discussionmentioning
confidence: 99%
“…Severe FXI deficiency is defined as activity level <20%, and partial or mild FXI deficiency is defined as levels between 20% and 60% 8 . However, the bleeding risk does not correlate well with FXI activity level, and the unpredictability of bleeding risk intraoperatively and postoperatively make the perioperative management of these patients particularly challenging 8,9 . Therapeutic agents available for management of FXI deficiency include FFP, FXI concentrate, antifibrinolytic agents such as ε‐aminocaproic acid or tranexamic acid, desmopressin, and low‐dose activated recombinant factor VII before surgery have been used to prevent bleeding complications 1 .…”
Section: Discussionmentioning
confidence: 99%